152 related articles for article (PubMed ID: 38697822)
21. Locoregional management of hepatic metastasis from primary uveal melanoma.
Sato T
Semin Oncol; 2010 Apr; 37(2):127-38. PubMed ID: 20494705
[TBL] [Abstract][Full Text] [Related]
22. [Therapy of metastatic malignant uveal melanoma].
Jäckel A; Bock M; Deichmann M; Waldmann V; Näher H
Hautarzt; 2001 Feb; 52(2):98-103. PubMed ID: 11244899
[TBL] [Abstract][Full Text] [Related]
23. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract][Full Text] [Related]
24. The treatment of metastatic uveal melanoma.
Pyrhönen S
Eur J Cancer; 1998 Jul; 34 Suppl 3():S27-30. PubMed ID: 9849406
[TBL] [Abstract][Full Text] [Related]
25. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
[TBL] [Abstract][Full Text] [Related]
26. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment.
Eskelin S; Pyrhönen S; Summanen P; Hahka-Kemppinen M; Kivelä T
Ophthalmology; 2000 Aug; 107(8):1443-9. PubMed ID: 10919885
[TBL] [Abstract][Full Text] [Related]
27. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
[TBL] [Abstract][Full Text] [Related]
28. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
[TBL] [Abstract][Full Text] [Related]
29. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
[TBL] [Abstract][Full Text] [Related]
30. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
[TBL] [Abstract][Full Text] [Related]
31. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
Sacco JJ; Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Holland C; Sato T
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844408
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors of liver metastases from uveal melanoma.
Kodjikian L; Grange JD; Baldo S; Baillif S; Garweg JG; Rivoire M
Graefes Arch Clin Exp Ophthalmol; 2005 Oct; 243(10):985-93. PubMed ID: 15891893
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of treatments for metastatic uveal melanoma.
Augsburger JJ; Corrêa ZM; Shaikh AH
Am J Ophthalmol; 2009 Jul; 148(1):119-27. PubMed ID: 19375060
[TBL] [Abstract][Full Text] [Related]
35. Uveal melanoma: implications of tumor doubling time.
Singh AD
Ophthalmology; 2001 May; 108(5):829-31. PubMed ID: 11319992
[No Abstract] [Full Text] [Related]
36. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.
Schuster R; Lindner M; Wacker F; Krössin M; Bechrakis N; Foerster MH; Thiel E; Keilholz U; Schmittel A
Melanoma Res; 2010 Jun; 20(3):191-6. PubMed ID: 20335820
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A
Front Oncol; 2023; 13():1167791. PubMed ID: 37207136
[TBL] [Abstract][Full Text] [Related]
38. Uveal melanoma: physiopathology and new in situ-specific therapies.
Souto EB; Zielinska A; Luis M; Carbone C; Martins-Gomes C; Souto SB; Silva AM
Cancer Chemother Pharmacol; 2019 Jul; 84(1):15-32. PubMed ID: 31079217
[TBL] [Abstract][Full Text] [Related]
39. Metastatic melanoma in the eye and orbit.
Zografos L; Ducrey N; Beati D; Schalenbourg A; Spahn B; Balmer A; Othenin-Girard CB; Chamot L; Egger E
Ophthalmology; 2003 Nov; 110(11):2245-56. PubMed ID: 14597536
[TBL] [Abstract][Full Text] [Related]
40. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
Klingenstein A; Haug AR; Zech CJ; Schaller UC
Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
